Answers are grounded in this paper and cite their sources.
Meeting abstracts Adoptive transfer of genetically-modified T cells is being explored as a salvage treatment for patients with selected metastatic cancers. Most of the current strategies utilize MHC class I-restricted T cell receptor (TCR) or chimeric antigen receptor (CAR) technologies to
No takes yet. Share an insight, caveat, or question.
Lu et al. (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: